3 Dividend Stocks to Double Up on Right Now

Three blue‑chip dividend names are pitched as buy‑the‑dip opportunities: Kraft Heinz, Kimberly‑Clark and Philip Morris. Kraft Heinz, which has seen shares fall roughly 65% since late 2025 and cut its quarterly payout to $0.40 in 2019, now yields about 6.5% and trades for under 10x forward earnings, with management planning a two‑company spinoff in H2 2026 that could unlock value if it follows a Kellogg‑style re‑rating. Kimberly‑Clark is buying Kenvue (Tylenol, Neutrogena, Listerine) with expected $2.1bn of cost synergies, a deal the piece says should be accretive and help sustain its 52‑year Dividend King streak (forward yield ~4.9%). Philip Morris’s pivot to smoke‑free products (IQOS and Zyn via Swedish Match) supports organic growth and dividend expansion potential; PMI trades at ~19x forward earnings with a ~3.7% yield, justifying a premium to Altria given steadier growth prospects.

Analysis

The article highlights three blue‑chip dividend names—Kraft Heinz (KHC), Kimberly‑Clark (KMB) and Philip Morris International (PM)—each portrayed as buy‑the‑dip opportunities. Kraft Heinz shares have fallen nearly 65% since late 2025, its quarterly dividend was cut from $0.625 to $0.40 in 2019, it now yields about 6.5% and trades for under 10x forward earnings, with management planning a two‑company spinoff in H2 2026 that could be a re‑rating catalyst.

Kimberly‑Clark is acquiring Kenvue with management citing $2.1 billion of cost synergies and a forward dividend yield of roughly 4.9%, which the article argues could preserve its 52‑year dividend growth streak if the deal is accretive. Philip Morris is positioned as a smoke‑free growth story—IQOS and Zyn after the Swedish Match purchase—and trades at ~19x forward earnings with a ~3.7% yield, a premium to Altria (noted at ~12x and a 7.1% yield) justified here by more certain growth prospects.

The investment case rests on execution: KHC’s spinoff must unlock value rather than prolong a yield trap, KMB must realize the $2.1bn of synergies to be accretive, and PM must sustain consumer adoption of smoke‑free products. Key near‑term monitoring points are spinoff timelines and disclosures for KHC, integration milestones and synergy delivery for KMB, and product adoption/organic growth metrics plus regulatory developments for PM.

Key Decisions for Investors

• Consider a small, tactical position in KHC as a catalyst play ahead of the H2 2026 spinoff but size exposure conservatively and monitor spinoff disclosures and cash‑flow guidance before increasing allocation
• Favor KMB on successful close of the Kenvue deal given the $2.1bn synergy target and 4.9% yield, but require visible integration milestones and realized cost savings before adding materially
• Maintain or modestly add to PM where the smoke‑free pivot (IQOS and Zyn) supports a ~19x forward P/E and 3.7% yield, while monitoring adoption trends and regulatory risk
• Across all three, prioritize catalyst monitoring (spinoff progress, synergy realization, product adoption), limit position sizes, and use hedges or stop rules to protect against execution risk